Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2015 1
2016 2
2017 1
2018 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Sands BE, et al. Among authors: o brien cd. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. N Engl J Med. 2019. PMID: 31553833 Free article. Clinical Trial.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Castro M, et al. Among authors: o brien c. Lancet Respir Med. 2015 May;3(5):355-66. doi: 10.1016/S2213-2600(15)00042-9. Epub 2015 Feb 23. Lancet Respir Med. 2015. PMID: 25736990 Clinical Trial.
INTERPRETATION: These results support the use of reslizumab in patients with asthma and elevated blood eosinophil counts who are inadequately controlled on inhaled corticosteroid-based therapy. FUNDING: Teva Branded Pharmaceutical Products R&D....
INTERPRETATION: These results support the use of reslizumab in patients with asthma and elevated blood eosinophil counts who are inadequatel …
Endothelial cell damage in idiopathic pneumonia syndrome.
Altmann T, Slack J, Slatter MA, O'Brien C, Cant A, Thomas M, Brodlie M, Annavarapu S, Gennery AR. Altmann T, et al. Among authors: o brien c. Bone Marrow Transplant. 2018 Apr;53(4):515-518. doi: 10.1038/s41409-017-0042-z. Epub 2018 Jan 15. Bone Marrow Transplant. 2018. PMID: 29335628 No abstract available.
Model-Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti-Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn Disease.
Zhou J, Xu Y, Chen Y, Shao J, Su Y, Xu Z, Zhou H, O'Brien C. Zhou J, et al. Among authors: o brien c. J Clin Pharmacol. 2023 Aug;63(8):928-942. doi: 10.1002/jcph.2252. Epub 2023 May 12. J Clin Pharmacol. 2023. PMID: 37060327 Clinical Trial.
No important covariates were identified in efficacy E-R analyses, overall, and in various subpopulations. No apparent E-R relationships were observed for the investigated safety end points. The PopPK and E-R analyses indicated that the inadequate efficacy of …
No important covariates were identified in efficacy E-R analyses, overall, and in various subpopulations. No apparent E-R rela …
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.
Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, Khaled AS, Ruiz P, Slapak-Green G, Lee M, Nery J, De Medina M, Tzakis A, Schiff ER. Neff GW, et al. Among authors: o brien cb. Transplantation. 2004 Nov 15;78(9):1303-7. doi: 10.1097/01.tp.0000129811.93072.1c. Transplantation. 2004. PMID: 15548967
This data reveals the difficulty and caution that must be taken when treating HCV-R liver-transplant recipients with combination pegylated alpha-2b interferon and ribavirin therapy....
This data reveals the difficulty and caution that must be taken when treating HCV-R liver-transplant recipients with combination pegy …